Mood disorders

Global Bipolar Depression Market Insight, Epidemiology and Market Forecast 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021

The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Bipolar Depression - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Bipolar Depression epidemiology division provides insights about the historical and current Bipolar Depression patient pool and forecasted trends for every seven major countries.
  • In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression.

Happify Launches the First Prescription Digital Therapeutics to Treat Both MDD and GAD

Retrieved on: 
Thursday, July 22, 2021

Designed as an adjunct to care for MDD and GAD, Ensemble must be prescribed by a clinician to treat these disorders.

Key Points: 
  • Designed as an adjunct to care for MDD and GAD, Ensemble must be prescribed by a clinician to treat these disorders.
  • Data shows that people with MDD are 5.7 times more likely to have GAD than people without MDD.
  • "Ensemble has been designed as a single treatment that targets underlying processes that are common to both MDD and GAD.
  • Recommendations provided by the device are adjunctive (supporting) and should not be solely or primarily relied upon to treat MDD or GAD.

Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board

Retrieved on: 
Tuesday, July 20, 2021

Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.

Key Points: 
  • Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.
  • Dr. Husain has published over 40 research papers investigating the neurobiology and associated clinical care of mood disorders.
  • Dr. Husains appointment is another important milestone in our journey to bring safer, more efficacious psychedelic-inspired mental illness treatments to the market.
  • Mindset was established in order to develop pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications

Retrieved on: 
Monday, July 19, 2021

The company plans to initiate its pivotal program for LYN-005, designed as the first-ever oral, ultra-long-acting, extended-release therapy, in early 2022.

Key Points: 
  • The company plans to initiate its pivotal program for LYN-005, designed as the first-ever oral, ultra-long-acting, extended-release therapy, in early 2022.
  • Both studies will evaluate LYN-005 at weekly doses ranging from 2 to 6 mg risperidone daily.
  • These studies will support indications in schizophrenia, bipolar mania, and bipolar 1 disorder.
  • We are grateful to the FDA for their guidance as we design this pivotal program.

Mantra Health Adds Bipolar I Disorder to its Telepsychiatry Treatments Helping College Students Get Diagnosed and Treated Early

Retrieved on: 
Wednesday, July 14, 2021

Mantra Health already supports bipolar II disorder through its collaborative telepsychiatry program and has seen successful outcomes in the 2020-2021 school year.

Key Points: 
  • Mantra Health already supports bipolar II disorder through its collaborative telepsychiatry program and has seen successful outcomes in the 2020-2021 school year.
  • Building on that success and recognizing there's a lack of care for students with Serious Mental Illnesses (SMIs) on college campuses, Mantra Health has added bipolar I disorder treatment to its program.
  • Bipolar disorder affects about 2.8% of the population in the U.S. overall, but roughly 3.2% of college students .
  • Adding treatment of bipolar I disorder doesn't change the extensive protocols around safety and risk that Mantra Health already has in place for students.

Gedeon Richter's first participation in the World Congress of Biological Psychiatry

Retrieved on: 
Wednesday, July 7, 2021

BUDAPEST, Hungary, July 7, 2021 /PRNewswire/ -- At the 15th World Congress of Biological Psychiatry, whichwas held virtually between the 28-30thJune 2021, Gedeon Richter Plc presented new analyses of cariprazine studies in form of two scientific posters and a free communication presentation.

Key Points: 
  • BUDAPEST, Hungary, July 7, 2021 /PRNewswire/ -- At the 15th World Congress of Biological Psychiatry, whichwas held virtually between the 28-30thJune 2021, Gedeon Richter Plc presented new analyses of cariprazine studies in form of two scientific posters and a free communication presentation.
  • Gedeon Richter organised and sponsored a satellite symposium where knowledgeable psychiatrists discussed the unmet medical needs and cariprazine's efficacy in the treatment of bipolar disorder.
  • Schizophrenia is a chronic psychiatric disorder that is comprised of positive, negative, and affective symptoms, as well as cognitive impairment.
  • The illness affects about 1% of the population globally; and an estimated 5 million people struggle with this disorder in the EU.

Gedeon Richter's first participation in the World Congress of Biological Psychiatry

Retrieved on: 
Wednesday, July 7, 2021

BUDAPEST, Hungary, July 7, 2021 /PRNewswire/ -- At the 15th World Congress of Biological Psychiatry, whichwas held virtually between the 28-30thJune 2021, Gedeon Richter Plc presented new analyses of cariprazine studies in form of two scientific posters and a free communication presentation.

Key Points: 
  • BUDAPEST, Hungary, July 7, 2021 /PRNewswire/ -- At the 15th World Congress of Biological Psychiatry, whichwas held virtually between the 28-30thJune 2021, Gedeon Richter Plc presented new analyses of cariprazine studies in form of two scientific posters and a free communication presentation.
  • Gedeon Richter organised and sponsored a satellite symposium where knowledgeable psychiatrists discussed the unmet medical needs and cariprazine's efficacy in the treatment of bipolar disorder.
  • Schizophrenia is a chronic psychiatric disorder that is comprised of positive, negative, and affective symptoms, as well as cognitive impairment.
  • The illness affects about 1% of the population globally; and an estimated 5 million people struggle with this disorder in the EU.

New Book Offers a Candid Look at Living with Bipolar Disorder

Retrieved on: 
Thursday, July 1, 2021

In Bipolar Chronicles Grippo takes readers into the mind of someone who is divorced from reality and delusional, sharing her thought patterns.

Key Points: 
  • In Bipolar Chronicles Grippo takes readers into the mind of someone who is divorced from reality and delusional, sharing her thought patterns.
  • She also supplies a list of helpful resources for those struggling with the disease.
  • What signs should they look for in those they suspect of having it?
  • It is valuable because people can understand what someone with bipolar disorder is going through, and that you can still be a functioning adult, working in a fabulous company.

OWP Pharmaceuticals Announces Patent Issuance for the First-Ever Oral Liquid Suspension of Quetiapine for the Treatment of Schizophrenia and Bipolar Disorder

Retrieved on: 
Thursday, July 1, 2021

OWP announced today that the United States Patent and Trademark Office (USPTO) has issued a patent to OWP for the first-ever oral liquid suspension of quetiapine.

Key Points: 
  • OWP announced today that the United States Patent and Trademark Office (USPTO) has issued a patent to OWP for the first-ever oral liquid suspension of quetiapine.
  • Quetiapine is an atypical antipsychotic and the tablets, for oral use, were first approved in the U.S. in 1997.
  • In schizophrenia, quetiapine is indicated for treatment in adolescents aged 13 to 17 years and adults.
  • It is also indicated as monotherapy for the acute treatment of depressive episodes in adult patients with bipolar I and bipolar II disorder.

Bipolar Depression Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021

This 'Bipolar Depression - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Key Points: 
  • This 'Bipolar Depression - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Bipolar Depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Bipolar Depression epidemiology division provides insights about the historical and current Bipolar Depression patient pool and forecasted trends for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Bipolar Depression epidemiology [segmented as Total Diagnosed Prevalent Cases of Bipolar Depression, Type-specific Diagnosed Prevalent Cases of Bipolar Depression, Severity-specific Diagnosed Prevalent Cases of Bipolar Depression, and Total Treated Cases of Bipolar Depression] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
  • The report provides the segmentation of the Bipolar Depression epidemiology by total diagnosed prevalent cases in the 7MM.